Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > RS

<< Previous

Bullboard Posts

Next >>

Post by crow27on Nov 30, 2020 12:35pm

741 Views

Post# 32001072

RS

If you have the goods a RS will not hurt you. It actually helps in that your share count drops dramatically. Now if you have nothing going for you and you are just trying to reduce your float then your stock will continue to slide after the split.
ATE is not in that situation as the good news is about to be announced and that will drive the stock higher. Remember a .10 cent gain or drop after the split is like us gaining or losing .01 cent before the split.
Nothing to fear about the RS, they are doing it from a situation of strength not weekness.

<< Previous

Bullboard Posts

Next >>

Online behaviour puts Canadians at risk of cyberattacks, study finds